{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-008188","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.756683+00:00","generated_at":"2026-06-17T12:30:16.688657+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DiaMedica reports FY2022 cash $33.5M, updates on ReMEDy2 clinical hold progress","bullets":["Cash and investments of $33.5M at Dec 31, 2022 vs $45.1M at end of 2021; cash runway into Q4 2024.","R&D expenses fell to $7.8M in 2022 from $8.8M; G&A expenses rose to $6.2M from $4.9M.","FDA clinical hold on ReMEDy2 remains; Part 1 in-use study completed, supports dose revision to avoid hypotension; Part 2 data due April 2023.","Phase 1C SAD study of DM199 started in Australia to confirm IV dose; enrollment underway, preliminary data expected May 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-008188","json":"https://secwatch.observer/filing/0001437749-23-008188.json","markdown":"https://secwatch.observer/filing/0001437749-23-008188.md","text":"https://secwatch.observer/filing/0001437749-23-008188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923008188/0001437749-23-008188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923008188/dmtp20230327_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:30:16.688657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d0c86564ee293e82cd33048d1a9f42b343ef57c","claim":"DiaMedica Therapeutics Inc. reported financial results for for the year ended December 31, 2022.","evidence_excerpt":"On March 28, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923008188/0001437749-23-008188-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}